With decades of research and new drugs approval, cancer remains to be the second leading cause of mortality worldwide. Faster and effective oncology drug development plus therapeutic innovation will continue drive double digit growth of oncology drug market to $80B by 2022.
Among global markets, Asia is well positioned to be the preferred destination for oncology drug development and clinical trials, because of its speed, cost-efficiency, and the similarity in standard treatment with US/Europe.
This webinar will be presented by experts from CMIC Group, Japan’s first and largest CRO. It will provide you tips and insights for early phase oncology drug development in Asia: the market trend, development strategy, regulatory requirements and a case study with step-by-step planning to ensure clinical trial success.